To be frank though, I thought fairly obvious in original announcement (re 76% of participants at 100% eradication). The % success rate not being divisible by 22 is a bit of a technicality and not really a problem unless you’re looking for a flaw (though easily explained nonetheless).
I agree that the Argonaut valuation seems conservative on a couple of fronts (both in acne valuation as Jonotron points out) and in applying a generic probability of trial success when safety profile arguably improves this probability significantly.
To be frank though, I thought fairly obvious in original...
-
- There are more pages in this discussion • 7,618 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
-0.005(1.32%) |
Mkt cap ! $678.7M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 35.5¢ | $2.388M | 6.527M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31921 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 132066 | 4 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |